Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Radiotherapy 11Fluorouracil 8Cisplatin 6Oxaliplatin 5Carboplatin 5Paclitaxel 4Neoadjuvant Therapy 4Leucovorin 4Gefitinib 4pembrolizumab 3Radiation 3Irinotecan 3Taxes 2Surgical Procedures, Operative 2Gemcitabine 2Docetaxel 2Cetuximab 2130-nm albumin-bound paclitaxel 2vandetanib 1spartalizumab 1sargramostim 1romidepsin 1ribociclib 1regorafenib 1oblimersen 1incomplete Freund's adjuvant 1fish oil triglycerides 1dehydroftorafur 1ceritinib 1benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma Of Esophagus × LY2940680 × Clear all
NCT02530437 2023-07-10

Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
7 enrolled 11 charts
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡